ImmuCell (ICCC)

• Market cap: $39.3M
• 1 day: 0.20%
• 5 days: 1.41%
• 1 month: -6.69%
• 3 months: 37.16%
• 6 months: 36.41%
• Year to date: -3.83%
• 1 year: 0.80%
• 5 years: -3.83%
• 10 years: -24.85%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Employees: 80

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

38% more capital invested

Capital invested by funds: $4.27M [Q3] → $5.89M (+$1.63M) [Q4]

14% more funds holding

Funds holding: 22 [Q3] → 25 (+3) [Q4]

1.9% less ownership

Funds ownership: 14.74% [Q3] → 12.84% (-1.9%) [Q4]

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7